Literature DB >> 21459804

Diagnosis of prostate cancer using differentially expressed genes in stroma.

Zhenyu Jia1, Yipeng Wang, Anne Sawyers, Huazhen Yao, Farahnaz Rahmatpanah, Xiao-Qin Xia, Qiang Xu, Rebecca Pio, Tolga Turan, James A Koziol, Steve Goodison, Philip Carpenter, Jessica Wang-Rodriguez, Anne Simoneau, Frank Meyskens, Manuel Sutton, Waldemar Lernhardt, Thomas Beach, Joseph Monforte, Michael McClelland, Dan Mercola.   

Abstract

More than one million prostate biopsies are performed in the United States every year. A failure to find cancer is not definitive in a significant percentage of patients due to the presence of equivocal structures or continuing clinical suspicion. We have identified gene expression changes in stroma that can detect tumor nearby. We compared gene expression profiles of 13 biopsies containing stroma near tumor and 15 biopsies from volunteers without prostate cancer. About 3,800 significant expression changes were found and thereafter filtered using independent expression profiles to eliminate possible age-related genes and genes expressed at detectable levels in tumor cells. A stroma-specific classifier for nearby tumor was constructed on the basis of 114 candidate genes and tested on 364 independent samples including 243 tumor-bearing samples and 121 nontumor samples (normal biopsies, normal autopsies, remote stroma, as well as stroma within a few millimeters of tumor). The classifier predicted the tumor status of patients using tumor-free samples with an average accuracy of 97% (sensitivity = 98% and specificity = 88%) whereas classifiers trained with sets of 100 randomly generated genes had no diagnostic value. These results indicate that the prostate cancer microenvironment exhibits reproducible changes useful for categorizing the presence of tumor in patients when a prostate sample is derived from near the tumor but does not contain any recognizable tumor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21459804      PMCID: PMC3071046          DOI: 10.1158/0008-5472.CAN-10-2585

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

Review 1.  Pathologic features the urologist should expect on a prostate biopsy.

Authors:  Mingxin Che; Wael Sakr; David Grignon
Journal:  Urol Oncol       Date:  2003 Mar-Apr       Impact factor: 3.498

2.  Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy.

Authors:  Andrew J Stephenson; Alex Smith; Michael W Kattan; Jaya Satagopan; Victor E Reuter; Peter T Scardino; William L Gerald
Journal:  Cancer       Date:  2005-07-15       Impact factor: 6.860

3.  Regularized linear discriminant analysis and its application in microarrays.

Authors:  Yaqian Guo; Trevor Hastie; Robert Tibshirani
Journal:  Biostatistics       Date:  2006-04-07       Impact factor: 5.899

4.  The FOXF2 pathway in the human prostate stroma.

Authors:  Leonie van der Heul-Nieuwenhuijsen; Natasja Dits; Wilfred Van Ijcken; Don de Lange; Guido Jenster
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

5.  Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model.

Authors:  Jennifer A Tuxhorn; Stephanie J McAlhany; Feng Yang; Truong D Dang; David R Rowley
Journal:  Cancer Res       Date:  2002-11-01       Impact factor: 12.701

6.  Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy.

Authors:  Badar M Mian; Yoshio Naya; Koji Okihara; Funda Vakar-Lopez; Patricia Troncoso; R Joseph Babaian
Journal:  Urology       Date:  2002-11       Impact factor: 2.649

7.  Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice.

Authors:  Leonard S Marks; David G Bostwick
Journal:  Rev Urol       Date:  2008

8.  Global gene expression analysis of reactive stroma in prostate cancer.

Authors:  Olga Dakhova; Mustafa Ozen; Chad J Creighton; Rile Li; Gustavo Ayala; David Rowley; Michael Ittmann
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

9.  Global expression analysis of prostate cancer-associated stroma and epithelia.

Authors:  Annely M Richardson; Karen Woodson; Yonghong Wang; Jaime Rodriguez-Canales; Heidi S Erickson; Michael A Tangrea; Kristian Novakovic; Sergio Gonzalez; Alfredo Velasco; Ernest S Kawasaki; Michael R Emmert-Buck; Rodrigo F Chuaqui; Audrey Player
Journal:  Diagn Mol Pathol       Date:  2007-12

10.  The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.

Authors:  Anne R Simoneau; Eugene W Gerner; Ray Nagle; Argyrios Ziogas; Sharon Fujikawa-Brooks; Hagit Yerushalmi; Thomas E Ahlering; Ronald Lieberman; Christine E McLaren; Hoda Anton-Culver; Frank L Meyskens
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-02       Impact factor: 4.254

View more
  50 in total

1.  Prostate cancer: biopsy samples from noncancerous stromal tissue can be used to diagnose nearby cancer.

Authors:  Annette Fenner
Journal:  Nat Rev Urol       Date:  2011-06-10       Impact factor: 14.432

2.  Coexpression and expression quantitative trait loci analyses of the angiogenesis gene-gene interaction network in prostate cancer.

Authors:  Hui-Yi Lin; Chia-Ho Cheng; Dung-Tsa Chen; Y Ann Chen; Jong Y Park
Journal:  Transl Cancer Res       Date:  2016-10       Impact factor: 1.241

3.  Overexpression of NCAPH is upregulated and predicts a poor prognosis in prostate cancer.

Authors:  Feilun Cui; Jianpeng Hu; Zhipeng Xu; Jian Tan; Huaming Tang
Journal:  Oncol Lett       Date:  2019-04-17       Impact factor: 2.967

Review 4.  Reprogramming of prostate cancer cells--technical challenges.

Authors:  Gisely T Borges; Eneida F Vêncio; Ricardo Z N Vêncio; Robert L Vessella; Carol B Ware; Alvin Y Liu
Journal:  Curr Urol Rep       Date:  2015-01       Impact factor: 3.092

5.  Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer.

Authors:  Tsz-Lun Yeung; Cecilia S Leung; Kay-Pong Yip; Jianting Sheng; Long Vien; Laura C Bover; Michael J Birrer; Stephen T C Wong; Samuel C Mok
Journal:  Clin Cancer Res       Date:  2019-07-22       Impact factor: 12.531

Review 6.  Miniaturized pre-clinical cancer models as research and diagnostic tools.

Authors:  Maria Håkanson; Edna Cukierman; Mirren Charnley
Journal:  Adv Drug Deliv Rev       Date:  2013-12-01       Impact factor: 15.470

Review 7.  Minireview: the molecular and genomic basis for prostate cancer health disparities.

Authors:  Isaac J Powell; Aliccia Bollig-Fischer
Journal:  Mol Endocrinol       Date:  2013-04-22

Review 8.  Zinc transporters in prostate cancer.

Authors:  M-C Franz; P Anderle; M Bürzle; Y Suzuki; M R Freeman; M A Hediger; G Kovacs
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun

9.  A cross-cancer differential co-expression network reveals microRNA-regulated oncogenic functional modules.

Authors:  Chen-Ching Lin; Ramkrishna Mitra; Feixiong Cheng; Zhongming Zhao
Journal:  Mol Biosyst       Date:  2015-12

10.  Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes.

Authors:  Matthew A Kinseth; Zhenyu Jia; Farahnaz Rahmatpanah; Anne Sawyers; Manuel Sutton; Jessica Wang-Rodriguez; Dan Mercola; Kathleen L McGuire
Journal:  Int J Cancer       Date:  2013-07-13       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.